Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Paul L. Hallenbeck"'
Autor:
Paul L. Hallenbeck, Christine L. Hann, P. Seshidhar Reddy, Kevin D. Burroughs, David Loesch, Joseph Stephenson, Neil N. Senzer, John T. Poirier, Charles M. Rudin
Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a first-in-human, first-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ceb98e7a80db18ee1e10421bf2db27
https://doi.org/10.1158/1078-0432.c.6518800.v1
https://doi.org/10.1158/1078-0432.c.6518800.v1
Autor:
Paul L. Hallenbeck, Christine L. Hann, P. Seshidhar Reddy, Kevin D. Burroughs, David Loesch, Joseph Stephenson, Neil N. Senzer, John T. Poirier, Charles M. Rudin
Supplementary Figure S1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fa2dd5ae0559aaa2fd3aab24639d7a0
https://doi.org/10.1158/1078-0432.22441945.v1
https://doi.org/10.1158/1078-0432.22441945.v1
Publikováno v:
Endocrine Abstracts.
Autor:
Huiyuan Zhang, Yuchen Du, Lin Qi, Sophie Xiao, Frank K Braun, Mari Kogiso, Aalaa Abdallah, Patricia A Baxter, Jack M Su, Daniel Brat, Paul L Hallenbeck, Wan-Yee Teo, Akash Patel, Xiao-Nan Li
Publikováno v:
Neuro-Oncology. 24:vii221-vii222
BACKGROUND Large panels of clinically relevant animal models are needed for the development of new therapies for GBM. SVV-001, a replication-competent oncolytic virus that can pass through the blood brain barrier, represents an attractive novel appro
Autor:
Paul L. Hallenbeck, Sunil Chada
Publikováno v:
Cancer Research. 82:6218-6218
Here we evaluated the efficacy of Seneca Valley Virus (SVV), an oncolytic virus in the Picornaviridae family, in combination with checkpoint inhibitors (CPI) using the CPI-resistant murine syngeneic pancreatic tumor model Pan02. SVV, serendipitously
Publikováno v:
Cancer Research. 81:LB039-LB039
Seneca Valley Virus (SVV-001) is an oncolytic virus that has only been tested as a single dose intravenous monotherapy in early clinical trials of patients having cancers with neuroendocrine properties (e.g., NET, NEC). Recent data in the oncolytic a
Autor:
Zhigang Liu, Xiumei Zhao, Hua Mao, Patricia A. Baxter, Yulun Huang, Litian Yu, Lalita Wadhwa, Jack M. Su, Adekunle Adesina, Lazlo Perlaky, Mary Hurwitz, Neeraja Idamakanti, Seshidhar Reddy Police, Paul L. Hallenbeck, Richard L. Hurwitz, Ching C. Lau, Murali Chintagumpala, Susan M. Blaney, Xiao-Nan Li
Publikováno v:
Neuro-Oncology. 15:1173-1185
Seneca Valley virus (SVV-001) is a nonpathogenic oncolytic virus that can be systemically administered and can pass through the blood-brain barrier. We examined its therapeutic efficacy and the mechanism of tumor cell infection in pediatric malignant
Autor:
Charles M. Rudin, Shawn S.-C. Li, Paul L. Hallenbeck, Neeraja Idamakanti, P. Seshidhar Reddy, Kevin D. Burroughs, John T. Poirier, Kristine L. Stump
Publikováno v:
Journal of General Virology. 93:2606-2613
Seneca Valley virus (SVV-001) is an oncolytic picornavirus with selective tropism for a subset of human cancers with neuroendocrine differentiation. To characterize further the specificity of SVV-001 and its patterns and kinetics of intratumoral spre
Autor:
Paul L. Hallenbeck, Margaret M. Willcocks, Elizabeth Royall, Zarmwa Gomwalk, Kevin D. Burroughs, Neeraja Idamakanti, Mehran Bakhshesh, P. Seshidhar Reddy, Graham J. Belsham, Lisa O. Roberts, Nicolas Locker
Publikováno v:
Journal of Virology. 85:4452-4461
The RNA genome of Seneca Valley virus (SVV), a recently identified picornavirus, contains an internal ribosome entry site (IRES) element which has structural and functional similarity to that from classical swine fever virus (CSFV) and hepatitis C vi
Autor:
Charles M. Rudin, Paul L. Hallenbeck, David M. Loesch, Kevin D. Burroughs, P. Seshidhar Reddy, Neil Senzer, Christine L. Hann, J. Stephenson, John T. Poirier
Publikováno v:
Clinical Cancer Research. 17:888-895
Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a first-in-human, first-in